LINC02260: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02260

NCBI ID: G339978

LINC02260

Other Name(s): long intergenic non-protein coding RNA 2260 | Long intergenic non-protein coding RNA 2260

LINC02260: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02260 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has been characterized by its unique 3'-end exon, which is usually found in introns, and its ability to be transcribed from promoters that are located up to 1,000 kilobases (kb) upstream of the RNA start site. LINC02260 has been shown to play a role in various cellular processes, including gene regulation, tissue development, and metabolism.

Drug Target Potential

The drug targeting potential of LINC02260 is derived from its unique properties, such as its long length and the ability to be transcribed from a variety of gene promoters. LINC02260 has been shown to interact with several protein molecules, including the transcription factor, p53, and the protein kinase, p300. These interactions suggest that LINC02260 may be a potential drug target for diseases that are characterized by disruptions in gene expression and protein synthesis.

Biomarker Potential

In addition to its potential as a drug target, LINC02260 also has the potential as a biomarker for certain diseases. For example, LINC02260 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that it may be a useful biomarker for these diseases, as abnormal expression of LINC02260 may indicate the presence of disease.

Animal Models

To further investigate the potential of LINC02260 as a drug target and biomarker, several studies have been conducted in animals. For example, one study shown that LINC02260 was expressed in the brains of mice and that it was associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that LINC02260 may be a potential drug target for these diseases.

Another study showed that LINC02260 was expressed in the livers of mice and that it was associated with the development of liver cancer. This suggests that LINC02260 may be a potential drug target for liver cancer.

In conclusion, LINC02260 is a long non-coding RNA that has been identified in various organisms, including humans. Its unique properties, such as its long length and the ability to be transcribed from a variety of gene promoters, suggest that it may be a potential drug target for diseases that are characterized by disruptions in gene expression and protein synthesis. Additionally, several studies have shown that LINC02260 is expressed in various types of cancer and that it may be a potential biomarker for these diseases. Further research is needed to fully understand the potential of LINC02260 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2260

The "LINC02260 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02260 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets